These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 10804727

  • 1. Echocardiographic evaluation of the ductal morphology in patients with refractoriness to lipo-prostaglandin E1 therapy.
    Takeda N, Hiraishi S, Misawa H, Agata Y, Horiguchi Y, Fujino N, Hirota H, Kawamura S, Ogawa N.
    Pediatr Int; 2000 Apr; 42(2):134-8. PubMed ID: 10804727
    [Abstract] [Full Text] [Related]

  • 2. Effect of Long-term Administration of Prostaglandin E1 on Morphologic Changes in Ductus Arteriosus.
    Iwaki R, Matsuhisa H, Minamisawa S, Akaike T, Hoshino M, Yagi N, Morita K, Shinohara G, Kaneko Y, Yoshitake S, Takahashi M, Tsukube T, Oshima Y.
    Ann Thorac Surg; 2020 Dec; 110(6):2088-2095. PubMed ID: 32246933
    [Abstract] [Full Text] [Related]

  • 3. Prostaglandin E1 in infants with congenital heart disease: Indian experience.
    Saxena A, Sharma M, Kothari SS, Juneja R, Reddy SC, Sharma R, Bhan A, Venugopal P.
    Indian Pediatr; 1998 Nov; 35(11):1063-9. PubMed ID: 10216540
    [Abstract] [Full Text] [Related]

  • 4. Aneurysmal dilatation of ductus arteriosus during lipo-prostaglandin E1 therapy for diaphragmatic hernia.
    Tohyama M, Baba A, Tsuno T, Aonuma K, Komiyama A.
    Eur J Pediatr; 1993 Nov; 152(11):877-9. PubMed ID: 8276014
    [Abstract] [Full Text] [Related]

  • 5. Vasodilating effect and tissue accumulation of prostaglandin E1 incorporated in lipid microspheres on the rat ductus arteriosus.
    Chino Y, Minagawa T, Kohno Y, Fukushima K, Momma K.
    Jpn J Pharmacol; 1999 Sep; 81(1):107-14. PubMed ID: 10580378
    [Abstract] [Full Text] [Related]

  • 6. Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions.
    Akkinapally S, Hundalani SG, Kulkarni M, Fernandes CJ, Cabrera AG, Shivanna B, Pammi M.
    Cochrane Database Syst Rev; 2018 Feb 27; 2(2):CD011417. PubMed ID: 29486048
    [Abstract] [Full Text] [Related]

  • 7. Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects.
    Tálosi G, Katona M, Rácz K, Kertész E, Onozó B, Túri S.
    J Perinat Med; 2004 Feb 27; 32(4):368-74. PubMed ID: 15346826
    [Abstract] [Full Text] [Related]

  • 8. Effects of liposomal prostaglandin E1 on periprocedural myocardial injury in patients with unstable angina undergoing an elective percutaneous coronary intervention.
    Fan Y, Jiang Y, Fu X, Cai J, Wang Y, Li W, Gu X, Xing K, Bai S, Bi X.
    Coron Artery Dis; 2015 Dec 27; 26(8):671-7. PubMed ID: 26267747
    [Abstract] [Full Text] [Related]

  • 9. Nursing care of the neonate receiving prostaglandin E1 therapy.
    Rikard DH.
    Neonatal Netw; 1993 Jun 27; 12(4):17-22. PubMed ID: 8510622
    [Abstract] [Full Text] [Related]

  • 10. Long beneficial effects after lipo-prostaglandin E1 administration on the ischemic gastric tube in pigs.
    Ikeda Y, Morita N.
    Dis Esophagus; 2008 Jun 27; 21(8):765-9. PubMed ID: 18564164
    [Abstract] [Full Text] [Related]

  • 11. [Intracavernous injection of lipo prostaglandin E1 for the diagnosis of impotence: a comparative study with prostaglandin E1-CD].
    Yajima M, Baba K, Minagawa N, Kohno S, Haraguchi C, Iwamoto T, Osada T.
    Hinyokika Kiyo; 1993 Mar 27; 39(3):289-92. PubMed ID: 8506803
    [Abstract] [Full Text] [Related]

  • 12. Progress in the prostaglandin E1-therapy of the intermittent claudication by means of bolus injections of LIPO-prostaglandin E1 (LIPO-PGE1).
    Scheffler P, Gross J, Markwirth T, Maier J, Schieffer H.
    Eur J Clin Pharmacol; 1996 Mar 27; 51(3-4):235-9. PubMed ID: 9010691
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical efficacy of different doses of lipo-prostaglandin E1 in the treatment of painful diabetic peripheral neuropathy.
    Hong L, Zhang J, Shen J.
    J Diabetes Complications; 2015 Mar 27; 29(8):1283-6. PubMed ID: 26355026
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prostaglandin E1 treatment of congenital heart disease: use prior to neonatal transport.
    Buck ML.
    DICP; 1991 Apr 27; 25(4):408-9. PubMed ID: 1926911
    [Abstract] [Full Text] [Related]

  • 17. An approach to predict the ductus-arteriosus dilating effect induced by lipo-prostaglandin E1 in newborn rats lacking plasma concentration-time data by the pharmacological response kinetic model.
    Yamauchi K, Yasunaga S, Kawasaki H, Kurosaki Y.
    Biol Pharm Bull; 2003 Feb 27; 26(2):210-5. PubMed ID: 12576682
    [Abstract] [Full Text] [Related]

  • 18. The role of age in determining the effects of lipo-PGE1 infusion on immediate arterial maximal flow velocity in patients with diabetes undergoing free flap surgery for lower extremity reconstruction: A prospective observational study.
    Park JY, Jin SJ, Suh HP, Lee SA, Cho C, Yu J, Hwang JH, Hong JP, Kim YK.
    J Plast Reconstr Aesthet Surg; 2020 May 27; 73(5):885-892. PubMed ID: 31924534
    [Abstract] [Full Text] [Related]

  • 19. Altered prostaglandin E1 dosage during extracorporeal membrane oxygenation in a newborn with ductal-dependent congenital heart disease.
    Stone DM, Frattarelli DA, Karthikeyan S, Johnson YR, Chintala K.
    Pediatr Cardiol; 2006 May 27; 27(3):360-3. PubMed ID: 16565906
    [Abstract] [Full Text] [Related]

  • 20. Echocardiographic evidence for a ductal tissue sling causing discrete coarctation of the aorta in the neonate: case report.
    Callahan PF, Quivers ES, Bradley LM, Sell JE, Martin GR.
    Pediatr Cardiol; 1998 May 27; 19(2):182-4. PubMed ID: 9565515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.